Johnson & Johnson (JNJ) Projected to Post Quarterly Earnings on Tuesday

Johnson & Johnson (NYSE:JNJ) is projected to release its Q3 2025 results before the market opens on Tuesday, October 14th. Analysts expect Johnson & Johnson to post earnings of $2.78 per share and revenue of $23.7258 billion for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, October 14, 2025 at 8:30 AM ET.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Trading Down 0.2%

JNJ opened at $190.66 on Monday. The stock has a market capitalization of $459.16 billion, a PE ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. The firm’s fifty day moving average price is $178.48 and its 200 day moving average price is $163.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $192.10.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on JNJ shares. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Morgan Stanley increased their target price on Johnson & Johnson from $176.00 to $178.00 and gave the stock an “equal weight” rating in a report on Friday. UBS Group set a $198.00 price objective on Johnson & Johnson in a research note on Friday, October 3rd. Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $192.94.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its position in Johnson & Johnson by 1.7% in the second quarter. California State Teachers Retirement System now owns 3,899,683 shares of the company’s stock worth $595,677,000 after purchasing an additional 65,322 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in shares of Johnson & Johnson by 1.9% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 2,950,858 shares of the company’s stock valued at $451,116,000 after purchasing an additional 54,894 shares in the last quarter. State of Tennessee Department of Treasury boosted its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. State of Tennessee Department of Treasury now owns 834,810 shares of the company’s stock valued at $127,517,000 after purchasing an additional 7,816 shares in the last quarter. Lazard Asset Management LLC lifted its stake in Johnson & Johnson by 13.0% during the second quarter. Lazard Asset Management LLC now owns 778,261 shares of the company’s stock valued at $118,878,000 after purchasing an additional 89,763 shares during the last quarter. Finally, Captrust Financial Advisors lifted its stake in Johnson & Johnson by 0.3% during the second quarter. Captrust Financial Advisors now owns 608,661 shares of the company’s stock valued at $92,973,000 after purchasing an additional 1,541 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.